353 related articles for article (PubMed ID: 12149228)
1. ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma.
Grønbaek K; Worm J; Ralfkiaer E; Ahrenkiel V; Hokland P; Guldberg P
Blood; 2002 Aug; 100(4):1430-7. PubMed ID: 12149228
[TBL] [Abstract][Full Text] [Related]
2. Ataxia telangiectasia gene mutations in leukaemia and lymphoma.
Boultwood J
J Clin Pathol; 2001 Jul; 54(7):512-6. PubMed ID: 11429421
[TBL] [Abstract][Full Text] [Related]
3. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances.
Camacho E; Hernández L; Hernández S; Tort F; Bellosillo B; Beà S; Bosch F; Montserrat E; Cardesa A; Fernández PL; Campo E
Blood; 2002 Jan; 99(1):238-44. PubMed ID: 11756177
[TBL] [Abstract][Full Text] [Related]
4. Comparison of ataxia-telangiectasia mutated protein expression in diffuse large B-cell lymphomas of primary central nervous system and non-central nervous system origin.
Kim SH; Cheong JW; Park KH; Kim TS; Yang WI
Arch Pathol Lab Med; 2007 Mar; 131(3):457-67. PubMed ID: 17516749
[TBL] [Abstract][Full Text] [Related]
5. Mutation of the ATM gene is not involved in the pathogenesis of either follicle center lymphoma or its transformation to higher-grade lymphoma.
Lossos IS; Thorstenson YR; Wayne TL; Oefner PJ; Levy R; Chu G
Leuk Lymphoma; 2002 May; 43(5):1079-85. PubMed ID: 12148890
[TBL] [Abstract][Full Text] [Related]
6. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas.
Tort F; Hernàndez S; Beà S; Martínez A; Esteller M; Herman JG; Puig X; Camacho E; Sánchez M; Nayach I; Lopez-Guillermo A; Fernández PL; Colomer D; Hernàndez L; Campo E
Blood; 2002 Dec; 100(13):4602-8. PubMed ID: 12393693
[TBL] [Abstract][Full Text] [Related]
7. Homozygous deletion of INK4a/ARF genes and overexpression of bcl-2 in relation with poor prognosis in immunocompetent patients with primary central nervous system lymphoma of the diffuse large B-cell type.
Hayashi Y; Iwato M; Arakawa Y; Fujisawa H; Thoma Y; Hasegawa M; Tachibana O; Yamashita J
J Neurooncol; 2001 Oct; 55(1):51-8. PubMed ID: 11804283
[TBL] [Abstract][Full Text] [Related]
8. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of the ATM gene in T-cell prolymphocytic leukemias.
Stoppa-Lyonnet D; Soulier J; Laugé A; Dastot H; Garand R; Sigaux F; Stern MH
Blood; 1998 May; 91(10):3920-6. PubMed ID: 9573030
[TBL] [Abstract][Full Text] [Related]
10. Frequent alterations of the p14(ARF) and p16(INK4a) genes in primary central nervous system lymphomas.
Nakamura M; Sakaki T; Hashimoto H; Nakase H; Ishida E; Shimada K; Konishi N
Cancer Res; 2001 Sep; 61(17):6335-9. PubMed ID: 11522621
[TBL] [Abstract][Full Text] [Related]
11. ATM mutations in sporadic lymphoid tumours.
Stankovic T; Stewart GS; Byrd P; Fegan C; Moss PA; Taylor AM
Leuk Lymphoma; 2002 Aug; 43(8):1563-71. PubMed ID: 12400598
[TBL] [Abstract][Full Text] [Related]
12. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
13. Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL.
Luo L; Lu FM; Hart S; Foroni L; Rabbani H; Hammarström L; Yuille MR; Catovsky D; Webster AD; Vorechovský I
Cancer Res; 1998 Jun; 58(11):2293-7. PubMed ID: 9622061
[TBL] [Abstract][Full Text] [Related]
14. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
Pettitt AR; Sherrington PD; Stewart G; Cawley JC; Taylor AM; Stankovic T
Blood; 2001 Aug; 98(3):814-22. PubMed ID: 11468183
[TBL] [Abstract][Full Text] [Related]
15. Clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukaemia.
Vorechovský I; Luo L; Dyer MJ; Catovsky D; Amlot PL; Yaxley JC; Foroni L; Hammarström L; Webster AD; Yuille MA
Nat Genet; 1997 Sep; 17(1):96-9. PubMed ID: 9288106
[TBL] [Abstract][Full Text] [Related]
16. Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukemia.
Schaffner C; Stilgenbauer S; Rappold GA; Döhner H; Lichter P
Blood; 1999 Jul; 94(2):748-53. PubMed ID: 10397742
[TBL] [Abstract][Full Text] [Related]
17. Genetic status of cell cycle regulators in squamous cell carcinoma of the oesophagus: the CDKN2A (p16(INK4a) and p14(ARF) ) and p53 genes are major targets for inactivation.
Smeds J; Berggren P; Ma X; Xu Z; Hemminki K; Kumar R
Carcinogenesis; 2002 Apr; 23(4):645-55. PubMed ID: 11960918
[TBL] [Abstract][Full Text] [Related]
18. Loss of the ARF tumor suppressor reverses premature replicative arrest but not radiation hypersensitivity arising from disabled atm function.
Kamijo T; van de Kamp E; Chong MJ; Zindy F; Diehl JA; Sherr CJ; McKinnon PJ
Cancer Res; 1999 May; 59(10):2464-9. PubMed ID: 10344759
[TBL] [Abstract][Full Text] [Related]
19. Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma.
Fang NY; Greiner TC; Weisenburger DD; Chan WC; Vose JM; Smith LM; Armitage JO; Mayer RA; Pike BL; Collins FS; Hacia JG
Proc Natl Acad Sci U S A; 2003 Apr; 100(9):5372-7. PubMed ID: 12697903
[TBL] [Abstract][Full Text] [Related]
20. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
